RenovoRx, Inc.
RNXT · NASDAQ
Bulios Fair Price
$1.13
33.1% downside
Current Price
$1.69
According to Bulios Fair Price, RNXT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
RenovoRx, Inc. (RNXT) is an American biotechnology company focused on developing innovative therapies for the treatment of hard-to-treat cancers. The company is developing advanced targeted treatment technologies that enable the direct delivery of chemotherapy to tumors with minimal impact on surrounding healthy tissues. The company's flagship product is the RenovoTAMP™ system, designed to improve the efficacy and reduce the side effects of cancer treatment. RenovoRx aims to provide new treatment options for patients with limited therapeutic alternatives. RenovoRx, Inc. (RNXT) shares could be an interesting choice for investors looking for opportunities in the biotechnology sector and innovative treatment technologies.
Sector
Healthcare
Industry
Biotechnology
CEO
Shaun R. Bagai
Employees
17
Headquarters
Mountain View
Upcoming events
Earnings
Upcoming earnings report